1.0Leitat Technological Centerhttps://leitat.org/es/Comunicación Leitathttps://leitat.org/es/blog/author/comunica-wp/rich600338<blockquote class="wp-embedded-content" data-secret="rmGHCH1Huc"><a href="https://leitat.org/es/blog/preclinonco/">PRECLINONCO</a></blockquote><iframe sandbox="allow-scripts" security="restricted" src="https://leitat.org/es/blog/preclinonco/embed/#?secret=rmGHCH1Huc" width="600" height="338" title="«PRECLINONCO» — Leitat Technological Center" data-secret="rmGHCH1Huc" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"></iframe><script> /*! This file is auto-generated */ !function(d,l){"use strict";l.querySelector&&d.addEventListener&&"undefined"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i<o.length;i++)o[i].style.display="none";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute("style"),"height"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):"link"===t.message&&(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document); //# sourceURL=https://leitat.org/wp-includes/js/wp-embed.min.js </script> https://leitat.org/wp-content/uploads/2014/08/biomed.jpg1152768PRECLINONCO Preclinical regulatory development of new oncological drug candidates ABSTRACT The PRECLINONCO project pursues the main objective of obtaining the data about preclinical efficacy, toxicity, pharmacokinetics, pharmacodynamics and manufacturability needed to have a group of 1-3 candidates for new oncology drugs. The project will overcome the preclinical stage of the candidates selection and the initial […]